Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPTEM for Newly Diagnosed Glioblastoma
NCT03213002Phase 2Recruiting
- Sponsor
- Northwell Health
- Start
- Jun 2017
- Primary completion
- Jun 2028
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in glioblastoma multiforme (GBM), sponsored by Northwell Health. Started Jun 2017; status: recruiting.
02
Drugs
capecitabine
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT03213002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03213002.